ASCO provisional clinical opinion: Epidermal growth factor receptor mutation testing in practice

Journal of Oncology Practice

Volumn 7, Issue 3, 2011, Pages 202-204

  Beasley, Mary Beth ^a,b   Milton, Daniel T ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Gynecologic Oncology of Indiana   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

CANCER PATIENT; CLINICAL PRACTICE; DNA DETERMINATION; EGFR GENE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NOTE; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECEPTOR GENE;

EID: 80052721913     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000166     Document Type: Note

References (24)

1. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472-8, 2008
2. Keedy V, Temin S, Somerfield M, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine-kinase (TKI) inhibitor therapy. J Clin Oncol doi: 10.1200/JCO.201031.8923
3. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-57, 2009
4. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2009
5. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
6. Lee JS, Park K, Kim SW: A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009 (abstract PRS. 4)
7. Reddy SK: ERCC, TS, RRM1, EGFR, and KRAS biomarker integration into a community-based medical oncology practice. J Clin Oncol 28:486s, 2010 (suppl; abstract 6156)
8. Dacic S: EGFR assays in lung cancer. Adv Anat Pathol 15:241-247, 2008
9. Sholl LM, Lindeman NI: Molecular diagnostics testing for lung adenocarcinoma: State-of-the-art in 2010. Pathol Case Rev 15:103-110, 2010
10. Smouse JH, Cibas ES, Janne PA, et al: EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 117:67-72, 2009
11. Boldrini L, Gisfredi S, Ursino S, et al: Mutational analysis in cytological specimens of advanced lung adenocarcinoma: A sensitive method for molecular diagnosis. J Thorac Oncol 2:1086-1090, 2007 (Pubitemid 350307900)
12. Nakajima T, Yasufuku K, Suzuki M, et al: Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 132:597-602, 2007 (Pubitemid 47282394)
13. Dacic S, Shuai Y, Yousem S, et al: Clinicopathological predictors of EGFR/ KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159- 168, 2009
14. Nakano H, Soda H, Takasu M, et al: Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 60:136-140, 2008 (Pubitemid 351434456)
15. Monaco SE, Nikiforova MN, Cieply K, et al: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 41:94- 102, 2010
16. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-55, 2005 (Pubitemid 40812628)
17. Chiosea S, Shuai Y, Cieply K, et al: EGFR fluorescence in situ hybridizationpositive lung adenocarcinoma: Incidence of coexisting KRAS and BRAF mutations. Hum Pathol 41:1053-1060, 2010
18. Sholl LM, Xiao Y, Joshi V, et al: EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry Am J Clin Pathol 133:922-934, 2010
19. Jeon YK, Sung SW, Chung JH, et al: Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54:387-398, 2006 (Pubitemid 44754719)
20. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005 (Pubitemid 47050841)
21. Taron M, Ichinose Y, Rosell R, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-585, 2005
22. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarkers analyses from a phase III, randomized, open-label, first-line study of gefitinib (g) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 27, 2009 (suppl; abstract 8006)
23. Sone T, Kasahara K, Kimura H, et al: Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 109:1836- 1844, 2007
24. Partners Healthcare: Price List & CPT Codes. http://pcpgm.partners. org/ lmm/ordering/prices-CPTcodes